Gilead, Leo Pharma

Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B
Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to $1.7B to jointly develop and commercialize LEO’s anti-inflammatory drugs. As part of the deal,
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than before, into inflammation, penning a major $1.7 billion deal with dermatology specialist Leo Pharma on the eve of the J.P. Morgan Healthcare conference.
Gilead, LEO Pharma partner to develop programs for inflammatory diseases
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases.
Gilead, LEO Pharma Enter Strategic Partnership To Accelerate Development Of Oral STAT6 Program
Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO
Gilead, Leo Pharma Form Pact Focused on Inflammatory Diseases
Gilead Sciences and LEO Pharma said they formed a strategic partnership to focus on the potential treatment of patients with inflammatory diseases.
Harbor Capital Advisors Inc. Buys 616 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Harbor Capital Advisors Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.3% during the 4th ...
FierceBiotech4d
Galapagos splits in 2, laying off 40% of staff, shrinking pipeline and ending Gilead partnership
After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...
Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD)
In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...
ST Germain D J Co. Inc. Sells 571 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
ST Germain D J Co. Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 15.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange ...
Hosted on MSN1d
Morgan Stanley Upgrades Gilead Sciences (GILD)
Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...
Zacks.com on MSN2d
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.
Morningstar5d
Gilead Sciences Inc GILD
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
The stock's rise snapped a five-day losing streak.